U.S. SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

(Check One):  |X| Form 10-K  |_| Form 20-F  |_| Form 11-K  |_| Form 10-Q
              |_| Form N-SAR

         For Period ended:  June 30, 2007
         |_| Transition Report on Form 10-K
         |_| Transition Report on Form 20-F
         |_| Transition Report on Form 11-K
         |_| Transition Report on Form 10-Q
         |_| Transition Report on Form N-SAR
         For the Transition Period Ended:______________________________

  Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has
                   verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates: N/A

PART I - REGISTRANT INFORMATION

Hemcure, Inc.
- --------------------------------------------------------------------------------
Full Name of Registrant

N/A
- --------------------------------------------------------------------------------
Former Name if Applicable

11839 East Smith Avenue
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)

Santa Fe Springs, California 90670
- --------------------------------------------------------------------------------
City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

         If the subject report could not be filed without unreasonable effort or
         expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
         following should be completed. (Check box if appropriate)

         (a) The reasons described in reasonable detail in Part III of this form
         could not be eliminated without unreasonable effort or expense;
|X|
         (b) The subject annual report, semi-annual report, transition report on
         Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be
         filed on or before the fifteenth calendar day following the prescribed
         due date; or the subject quarterly report or transition report on Form
         10-Q, or portion thereof will be filed on or before the fifth calendar
         day following the prescribed due date.

         (c) The accountant's statement or other exhibit required by Rule
         12b-25(c) has been attached if applicable.



PART III- NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof could not be filed within the
prescribed period.

         The registrant is waiting for the completion of a valuation report
         that is necessary for the preparation of its balance sheet.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this
notification

Arthur Liu                      562                  447-1780
- --------------------------------------------------------------------------
(Name)                          (Area Code)          (Telephone Number)

(2) Have all other periodic reports required under section 13 or 15(d) of the
Securities Exchange Act of 1934 or section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s). |X| Yes |_| No

(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
|X| Yes |_| No

If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

                    Hemcure, Inc.
- --------------------------------------------------------------------------
                  (Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date: September 24, 2007

/s/ Arthur Liu
- --------------------------------------------
Arthur Liu, Chief Financial Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

                                    ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).



Hemcure, Inc.
Attachment Part IV, item (3)
Form 12b-25
Annual Report on Form 10-KSB for the period ended June 30, 2007

On June 7, 2007, the registrant acquired AuraSound, Inc. in a stock acquisition.
In accordance with FAS 141, the registrant is working with valuation experts to
establish valuations for the assets acquired including patents, trademarks,
assembled workforce and other intangible assets in addition to the hard assets
acquired.

The reporting period that ended June 30, 2007 will only include the operating
results of AuraSound, Inc. for the period from acquisition (June 7, 2007)
through June 30, 2007. As a result, the registrant expects sales revenue to be
approximately $209,000, with costs and expenses expected to be about $489,000.
The registrant had no revenue during the prior year period and had a loss of
$33,209.